# FIM-NL - First-in-Man Study (Netherlands Part) With Sirolimus Coated Modified BX Velocity Stent

> **NCT00233818** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cordis US Corp.** · enrollment: 15 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DEVICE:** Sirolimus-coated Bx VELOCITY Stent

## Key facts

- **NCT ID:** NCT00233818
- **Lead sponsor:** Cordis US Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02
- **Primary completion:** —
- **Final completion:** 2005-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2007-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00233818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00233818, "FIM-NL - First-in-Man Study (Netherlands Part) With Sirolimus Coated Modified BX Velocity Stent". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00233818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*